Phoenix Life Sciences International Limited ("Phoenix Life") entered into an agreement to acquire Phoenix Life Sciences International Limited (OTCPK:PLSI) ("Phoenix") in a reverse merger transaction on September 18, 2018. As per the agreement, Phoenix will exchange its common stock with Phoenix Life shareholders at a 1:1 ratio. Russell Stone resigned as Director of Phoenix and Stephen Cornford, Janelle Mardsen, Geoff Boynton and Martin Tindall will be appointed to the Phoenix Board of Directors, and Martin Tindall will be named the Phoenix Chief Executive Officer. Immediately after the closing, Phoenix will reappoint Lewis Humer as Director. The respective Boards of Directors of Phoenix Life and Phoenix have approved the merger. The transaction is expected to close on September 18, 2018. Phoenix Life Sciences International Limited ("Phoenix Life") completed the acquisition of Phoenix Life Sciences International Limited (OTCPK:PLSI) ("Phoenix") in a reverse merger transaction on September 18, 2018. Phoenix issued 29.8 million common stock bearing the restricted legend without registration.